The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020

Abstract

BackgroundThe World Health Organization (WHO) released revised guidelines in 2015 recommending that all people living with HIV, regardless of CD4 count, initiate antiretroviral therapy (ART) upon diagnosis. However, few studies have projected the global resources needed for rapid scale-up of ART. Under the Health Policy Project, we conducted modeling analyses for 97 countries to estimate eligibility for and numbers on ART from 2015 to 2020, along with the facility-level financial resources required. We compared the estimated financial requirements to estimated funding available.Methods and FindingsCurrent coverage levels and future need for treatment were based on country-specific epidemiological and demographic data. Simulated annual numbers of individuals on treatment were derived from three scenarios: (1) continuation of countries’ current policies of eligibility for ART, (2) universal adoption of aspects of the WHO 2013 eligibility guidelines, and (3) expanded eligibility as per the WHO 2015 guidelines and meeting the Joint United Nations Programme on HIV/AIDS “90-90-90” ART targets. We modeled uncertainty in the annual resource requirements for antiretroviral drugs, laboratory tests, and facility-level personnel and overhead.We estimate that 25.7 (95% CI 25.5, 26.0) million adults and 1.57 (95% CI 1.55, 1.60) million children could receive ART by 2020 if countries maintain current eligibility plans and increase coverage based on historical rates, which may be ambitious. If countries uniformly adopt aspects of the WHO 2013 guidelines, 26.5 (95% CI 26.0 27.0) million adults and 1.53 (95% CI 1.52, 1.55) million children could be on ART by 2020. Under the 90-90-90 scenario, 30.4 (95% CI 30.1, 30.7) million adults and 1.68 (95% CI 1.63, 1.73) million children could receive treatment by 2020. The facility-level financial resources needed for scaling up ART in these countries from 2015 to 2020 are estimated to be US$45.8 (95% CI 45.4, 46.2) billion under the current scenario, US$48.7 (95% CI 47.8, 49.6) billion under the WHO 2013 scenario, and US$52.5 (95% CI 51.4, 53.6) billion under the 90-90-90 scenario. After projecting recent external and domestic funding trends, the estimated 6-y financing gap ranges from US$19.8 billion to US$25.0 billion, depending on the costing scenario and the U.S. President’s Emergency Plan for AIDS Relief contribution level, with the gap for ART commodities alone ranging from US$14.0 to US$16.8 billion.The study is limited by excluding above-facility and other costs essential to ART service delivery and by the availability and quality of country- and region-specific data.ConclusionsThe projected number of people receiving ART across three scenarios suggests that countries are unlikely to meet the 90-90-90 treatment target (81% of people living with HIV on ART by 2020) unless they adopt a test-and-offer approach and increase ART coverage. Our results suggest that future resource needs for ART scale-up are smaller than stated elsewhere but still significantly threaten the sustainability ...

Population uptake and effectiveness of test‐and‐treat antiretroviral therapy guidelines for preventing the global spread of HIV: an ecological cross‐national analysis

“…Our findings are consistent with those of other studies. First, the association between test-and-treat and higher ART coverage is both intuitive and consistent with the findings of other studies showing earlier initiation of ART to be associated with increased ART coverage [51,52].…”

“…Our findings are consistent with those of other studies. First, the association between test‐and‐treat and higher ART coverage is both intuitive and consistent with the findings of other studies showing earlier initiation of ART to be associated with increased ART coverage . Secondly, the association between test‐and‐treat and greater population‐level viral suppression among people on ART is also consistent with the results of several studies that reported that increased ART coverage and earlier initiation of ART were linked to improved HIV outcomes , including attainment of viral suppression and reduced transmission and incidence .…”

Oxidative and Nitrosative Stress as Well as the Tryptophan Catabolites Pathway in Depressive Disorders

“…The total cost of treating depression in the United States is about $ 83.1 billion per year. For comparison, the costs of heart failure treatment total about $ 39.2 billion, and in the case of AIDS -about $ 50 billion per year (Dutta et al 2015, Greenberg et al 2015, Voigt et al 2015.…”

Prevention literacy: community‐based advocacy for access and ownership of the HIV prevention toolkit

“…To interpret meaning from the content of text data and to understand the depth and scope of the literature as related to the evolving HIV and AIDS epidemic, our analysis was informed by conceptualizations on distinct social, historical, and behavioural grouping in the three decades of the global response to HIV [14]. Analytic codes were defined prior to search (e.g.…”